Study guide

4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

Key Takeaways Explain This Topic AI

Heart failure is categorized by left ventricular ejection fraction into HFrEF (LVEF ≤40%), HFmrEF (LVEF 41–49%), and HFpEF (LVEF ≥50%); Guideline-Directed Medical Therapy (GDMT) for HFrEF mandates four foundational mortality-reducing drug classes: ARNI (sacubitril/valsartan), Evidence-Based Beta-Blocker (carvedilol, metoprolol succinate, bisoprolol), Mineralocorticoid Receptor Antagonist (spironolactone/eplerenone), and SGLT2 Inhibitor (dapagliflozin/empagliflozin).

When transitioning a patient from an ACE inhibitor to an ARNI (sacubitril/valsartan), a mandatory 36-hour washout period is required to prevent life-threatening angioedema from dual inhibition of bradykinin degradation; serum NT-proBNP must be used for monitoring because sacubitril inhibits neprilysin, falsely elevating standard BNP.

SGLT2 inhibitors (empagliflozin, dapagliflozin) carry a Class 1 recommendation across the entire ejection fraction spectrum, including HFpEF (LVEF ≥50%) and HFmrEF (41–49%), significantly reducing heart failure hospitalizations and cardiovascular mortality.

Atrial Fibrillation stroke risk is stratified using the CHA2DS2-VASc score; oral anticoagulation is strongly recommended for scores ≥2 in men or ≥3 in women, with Direct Oral Anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran) preferred over Warfarin for non-valvular AFib due to superior safety and lower intracranial hemorrhage risk.

Peripheral Artery Disease (PAD) is diagnosed via resting Ankle-Brachial Index (ABI ≤0.90 is diagnostic; ABI >1.40 indicates non-compressible calcified vessels requiring Toe-Brachial Index); management includes high-intensity statin, smoking cessation, antiplatelet therapy, Supervised Exercise Therapy (first-line for claudication), and cilostazol (strictly contraindicated in heart failure of any severity).

Last updated: August 2026

Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

Cardiovascular disorders in aging adults rarely occur in isolation. The clinical triad of Heart Failure (HF) , Atrial Fibrillation (AFib) , and Peripheral Vascular Disease (PVD/PAD) represents a complex web of neurohormonal activation, hemodynamic stress, and vascular calcification. Heart failure affects over 6.5 million Americans, AFib increases ischemic stroke risk fivefold, and lower extremity peripheral artery disease serves as a potent harbinger of systemic cardiovascular mortality.

For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board certification demands mastery of the 2022 AHA/ACC/HFSA Heart Failure Guidelines, the four foundational pillars of Guideline-Directed Medical Therapy (GDMT), CHA 2 DS 2 -VASc \text{CHA}_2\text{DS}_2\text{-VASc} CHA 2 ​ DS 2 ​ -VASc anticoagulation protocols, and the non-invasive vascular evaluation of claudication and limb ulcerations.

1. Heart Failure Classification & The Staging Continuum

The 2022 AHA/ACC/HFSA guidelines classify heart failure according to Left Ventricular Ejection Fraction (LVEF) measured by echocardiography, alongside a 4-stage disease progression model. +-----------------------------------------------------------------------------+

  • | HEART FAILURE CLASSIFICATION BY EJECTION FRACTION |
  • | |
  • | PHENOTYPE LVEF CRITERIA PATHOPHYSIOLOGICAL FOCUS |
  • | ----------------------------------------------------------------------- |
  • | HFrEF (Reduced EF) <= 40% Systolic pump failure, |
  • | eccentric remodeling |
  • | HFmrEF (Mildly Reduced EF) 41% to 49% Intermediate phenotype, |
  • | benefits from HFrEF GDMT |
  • | HFpEF (Preserved EF) >= 50% Diastolic relaxation |
  • | failure, high filling |
  • | pressures, stiff LV |
  • | HFimpEF (Improved EF) Baseline <= 40%, Recovered systolic |
  • | >= 10-point rise, function; MUST CONTINUE |
  • | second LVEF > 40% GDMT indefinitely! |
  • +-----------------------------------------------------------------------------+

AHA/ACC Stages of Heart Failure vs. NYHA Functional Classes +-----------------------------------------------------------------------------+

  • | AHA/ACC STAGES VS. NYHA FUNCTIONAL CLASSIFICATION |
  • | |
  • | ACC/AHA STAGES (Progression of Disease - CANNOT MOVE BACKWARD): |
  • | * STAGE A: At Risk for HF (HTN, DM, ASCVD, obesity, family history; |
  • | no structural disease or symptoms). |
  • | * STAGE B: Pre-Heart Failure (Structural heart disease, LVH, reduced LVEF,|
  • | or elevated BNP/cTn; NO prior or current symptoms). |
  • | * STAGE C: Symptomatic Heart Failure (Structural disease WITH current or |
  • | prior symptoms of heart failure). |
  • | * STAGE D: Advanced Heart Failure (Refractory end-stage symptoms at rest |
  • | interfering with daily life despite maximal GDMT). |
  • | |
  • | NYHA FUNCTIONAL CLASSES (Functional Capacity - FLUCTUATES OVER TIME): |
  • | * CLASS I: No limitation of physical activity. Ordinary activity |
  • | does not cause undue fatigue, palpitation, or dyspnea. |
  • | * CLASS II: Slight limitation of physical activity. Comfortable at rest; |
  • | ordinary physical activity results in symptoms. |
  • | * CLASS III: Marked limitation of physical activity. Comfortable at rest; |
  • | less than ordinary activity causes fatigue or dyspnea. |
  • | * CLASS IV: Unable to carry on any physical activity without discomfort. |
  • | Symptoms of heart failure present AT REST. |
  • +-----------------------------------------------------------------------------+
  • 2. Diagnostic Workup & Biomarker Kinetics: BNP vs. NT-proBNP

When evaluating acute or chronic dyspnea, circulating natriuretic peptides provide vital diagnostic and prognostic information. +-----------------------------------------------------------------------------+

  • | NATRIURETIC PEPTIDE SYNTHESIS & CLEAVAGE |
  • | |
  • | [VENTRICULAR MYOCYTE MYOCARDIAL WALL STRETCH] |
  • | | |
  • | v |
  • | [PRO-BNP (108 Amino Acids)] |
  • | | (Cleaved by Furin / Corin) |
  • | +----------------+----------------+ |
  • | | | |
  • | v v |
  • | [BNP (Active Hormone)] [NT-proBNP (Inactive Fragment)] |
  • | - 32 Amino Acids - 76 Amino Acids |
  • | - Half-life: 20 minutes - Half-life: 70-120 minutes |
  • | - Cleared by: NEPRILYSIN & - Cleared by: RENAL FILTRATION |
  • | NPR-C clearance receptors (Sensitive to kidney dysfunction) |
  • +-----------------------------------------------------------------------------+

Clinical Biomarker Nuances & The ARNI Effect:

Diagnostic Cutoffs for Acute Dyspnea Exclusion:

BNP < 100 pg/mL <100\text{ pg/mL} < 100 pg/mL or NT-proBNP < 300 pg/mL <300\text{ pg/mL} < 300 pg/mL has a ≥ 98 % \ge 98\% ≥ 98% negative predictive value to rule out heart failure.

Age-stratified NT-proBNP rule-in thresholds for acute HF: Age < 50 <50 < 50 ( > 450 pg/mL >450\text{ pg/mL} > 450 pg/mL ); Age 50–75 ( > 900 pg/mL >900\text{ pg/mL} > 900 pg/mL ); Age > 75 >75 > 75 ( > 1 , 800 pg/mL >1,800\text{ pg/mL} > 1 , 800 pg/mL ).

The ARNI (Sacubitril) Biomarker Trap:

Sacubitril is a neprilysin inhibitor . Because neprilysin is the primary enzyme responsible for degrading biologically active BNP , patients on sacubitril/valsartan will exhibit paradoxically elevated BNP levels that do not reflect worsening heart failure.

In contrast, NT-proBNP is NOT a substrate for neprilysin (it is cleared solely by the kidneys). Therefore, in patients taking an ARNI, NT-proBNP must be used exclusively to assess disease severity and monitor clinical decompensation.

Obesity Effect: Patients with a BMI ≥ 30 kg/m 2 \text{BMI} \ge 30\text{ kg/m}^2 BMI ≥ 30 kg/m 2 have significantly lower circulating baseline BNP/NT-proBNP levels (~50% lower) due to increased adipose clearance receptor expression.

3. Guideline-Directed Medical Therapy (GDMT) for HFrEF: The Four Foundational Pillars

The 2022 AHA/ACC/HFSA guidelines establish that all patients with HFrEF (LVEF ≤ 40 % \le 40\% ≤ 40% ) should be initiated on The Four Foundational Pillars of GDMT simultaneously or in rapid succession, as this combination reduces all-cause mortality by over 73% compared to placebo. +-----------------------------------------------------------------------------+

  • | THE FOUR FOUNDATIONAL PILLARS OF HFrEF GDMT |
  • | |
  • | [PILLAR 1: ARNI (OR ACEi / ARB)] |
  • | * Sacubitril/Valsartan (24/26 mg to 97/103 mg BID) - PREFERRED FIRST-LINE |
  • | * PARADIGM-HF: 20% reduction in CV death / HF hospitalization vs enalapril|
  • | * MANDATORY: 36-hour washout when switching from ACE inhibitor! |
  • | |
  • | [PILLAR 2: EVIDENCE-BASED BETA-BLOCKER] |
  • | * Specifically: Carvedilol, Metoprolol Succinate ER, or Bisoprolol |
  • | * Must be clinically euvolemic before initiation; start low, titrate slow |
  • | * Note: Atenolol, Metoprolol Tartrate do NOT reduce HFrEF mortality! |
  • | |
  • | [PILLAR 3: MINERALOCORTICOID RECEPTOR ANTAGONIST (MRA)] |
  • | * Spironolactone (12.5-25 mg daily) or Eplerenone (25-50 mg daily) |
  • | * RALES / EMPHASIS-HF: 30% mortality reduction; slows cardiac fibrosis |
  • | * Criteria: Serum K+ < 5.0 mEq/L and eGFR >= 30 mL/min |
  • | |
  • | [PILLAR 4: SGLT2 INHIBITOR] |
  • | * Dapagliflozin (10 mg daily) or Empagliflozin (10 mg daily) |
  • | * DAPA-HF / EMPEROR-Reduced: Reduces CV death / HF hospitalization |
  • | * Effective in BOTH diabetic and non-diabetic patients; eGFR >= 20-25 |
  • +-----------------------------------------------------------------------------+
  • Comprehensive GDMT Pharmacotherapy & Safety Matrix

Drug Class & Agents Target Dosing Mechanism of Benefit Monitoring, Adverse Effects & Pearls

ARNI ; Sacubitril / Valsartan (Entresto) Initial: 24/26 mg or 49/51 mg BID; Target: 97/103 mg BID Neprilysin inhibition (increases natriuretic peptides, bradykinin, adrenomedullin) + AT1 receptor blockade. Mandatory 36-hour washout from ACEi to avoid severe angioedema. Hypotension (more than ACEi), hyperkalemia, renal impairment. Use NT-proBNP to monitor.

Evidence-Based Beta-Blockers ; Carvedilol (3.125–25 mg BID); Metoprolol Succinate (12.5–200 mg daily); Bisoprolol (1.25–10 mg daily) Titrate q2–4 weeks to maximum tolerated target dose Reverses chronic sympathetic toxicity, downregulates β \beta β -receptors, prevents ventricular remodeling, antiarrhythmic. Initiate only when clinically euvolemic (not in acute decompensated HF). May cause transient fluid retention; do not abruptly stop.

MRA ; Spironolactone (12.5–50 mg daily); Eplerenone (25–50 mg daily) Target: 25–50 mg daily Blocks aldosterone in collecting duct and myocardium; prevents myocardial fibrosis, collagen deposition, and potassium wasting. Check K+ and renal function at 1 week, 4 weeks, and q6m. Contraindicated if K + > 5.0 mEq/L \text{K}^+ > 5.0\text{ mEq/L} K + > 5.0 mEq/L or eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min . Gynecomastia with spironolactone (switch to eplerenone).

SGLT2 Inhibitor ; Dapagliflozin (10 mg daily); Empagliflozin (10 mg daily) 10 mg daily (no titration needed) Promotes osmotic natriuresis, shifts myocardial fuel to ketones, reduces interstitial edema, decreases intraglomerular pressure. Class 1 across all LVEF (HFrEF, HFmrEF, HFpEF) . Benefits independent of diabetes. Risks: Mycotic genital infections, euglycemic DKA (in diabetics), mild volume depletion.

Loop Diuretics ; Furosemide (20–160 mg); Torsemide (10–40 mg); Bumetanide (0.5–4 mg) Titrate to achieve euvolemia (dry weight) Inhibits Na + / K + / 2 Cl − \text{Na}^+/\text{K}^+/2\text{Cl}^- Na + / K + /2 Cl − in thick ascending limb of Henle; relieves pulmonary and peripheral congestion. Symptom relief only (does NOT reduce mortality) . Over-diuresis causes prerenal azotemia and electrolyte wasting (hypokalemia, hypomagnesemia).

Hydralazine + Isosorbide Dinitrate (BiDil) Target: Hydralazine 75 mg / ISDN 40 mg TID Direct arterial vasodilator + venodilator (reduces afterload and preload; nitric oxide enhancement). Indicated in self-identified Black patients with NYHA III–IV symptoms on optimal GDMT (A-HeFT trial: 43% mortality reduction), or in patients intolerant to ARNI/ACEi/ARB due to severe renal failure/hyperkalemia.

4. Evidence-Based Management of HFpEF & HFmrEF

Heart Failure with Preserved Ejection Fraction (HFpEF, LVEF ≥ 50 % \text{LVEF} \ge 50\% LVEF ≥ 50% ) represents over half of all heart failure cases in patients > 65 >65 > 65 years, driven by obesity, hypertension, arterial stiffness, and diabetic microvascular inflammation.

SGLT2 Inhibitors (Class 1 Recommendation): The milestone EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) trials demonstrated significant reductions in cardiovascular death and HF hospitalizations in HFpEF and HFmrEF, establishing SGLT2 inhibitors as the first foundational therapy for preserved ejection fraction.

Loop Diuretics: Titrated to manage pulmonary congestion and peripheral edema.

MRAs (Spironolactone): Class 2b recommendation (TOPCAT trial demonstrated reduced hospitalizations, especially in patients with LVEF at the lower end of the preserved spectrum: 45–57%).

ARNI (Sacubitril/Valsartan): Class 2b recommendation (PARAGON-HF trial showed benefits in hospitalizations in patients with lower LVEF and females).

Blood Pressure & Atrial Fibrillation Control: Target SBP < 130 mmHg \text{SBP} < 130\text{ mmHg} SBP < 130 mmHg ; rapid AFib shortens diastolic filling time, precipitating acute pulmonary edema in stiff ventricles.

5. Atrial Fibrillation: Presentation, Rate vs. Rhythm & Instability

Atrial Fibrillation (AFib) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation and chaotic, irregular ventricular response. +-----------------------------------------------------------------------------+

  • | ATRIAL FIBRILLATION 12-LEAD ECG |
  • | |
  • | 1. "IRREGULARLY IRREGULAR" R-R intervals (no repeating pattern) |
  • | 2. ABSENCE OF DISCRETE P WAVES (replaced by fibrillatory 'f' waves: 350-600/min)|
  • | 3. Narrow QRS complexes (unless bundle branch block or aberrancy present) |

+-----------------------------------------------------------------------------+ +-----------------------------------------------------------------------------+

  • | ATRIAL FIBRILLATION MANAGEMENT ALGORITHM |
  • | |
  • | [PATIENT IN ATRIAL FIBRILLATION] |
  • | | |
  • | +--------------------------+--------------------------+ |
  • | | | |
  • | v v |
  • | [HEMODYNAMICALLY UNSTABLE] [HEMODYNAMICALLY STABLE]|
  • | - Sustained hypotension / shock - Rate vs Rhythm |
  • | - Acute altered mental status - Assess stroke risk |
  • | - Refractory ischemic chest pain - Anticoagulation |
  • | - Acute flash pulmonary edema | |
  • | | v |
  • | v [RATE CONTROL] |
  • | [IMMEDIATE SYNCHRONIZED - Beta-Blocker OR |
  • | DIRECT-CURRENT CARDIOVERSION (DCCV)] - Non-DHP CCB |
  • | - Goal HR < 80 (rest) |
  • +-----------------------------------------------------------------------------+

Clinical Management Strategies:

Rate Control (First-Line in Most Older Adults):

Beta-Blockers: Metoprolol, Atenolol, Carvedilol (preferred in CAD or HFrEF).

Non-Dihydropyridine CCBs: Diltiazem or Verapamil ( Strictly avoid in HFrEF / LVEF ≤40% due to negative inotropic depression).

Digoxin: Useful adjunct in sedentary elders or co-existing HFrEF; narrow therapeutic window ( 0.5 – 0.9 ng/mL 0.5–0.9\text{ ng/mL} 0.5–0.9 ng/mL ).

Target Heart Rate: Resting HR < 80 bpm <80\text{ bpm} < 80 bpm (symptomatic) or < 110 bpm <110\text{ bpm} < 110 bpm (lenient rate control per RACE II trial if asymptomatic and LV function preserved).

Rhythm Control (Restoration of Sinus Rhythm): Preferred in younger patients, highly symptomatic individuals, heart failure triggered by AFib (tachycardia-induced cardiomyopathy), or failure of rate control. Modalities: Antiarrhythmic drugs (Amiodarone, Dofetilide, Flecainide [avoid flecainide in structural/ischemic heart disease]), synchronized cardioversion, and Catheter Pulmonary Vein Isolation (PVI) Ablation.

6. Stroke Risk Stratification: CHA2DS2-VASc & Anticoagulation Protocols

Ischemic stroke in AFib results from blood stasis in the Left Atrial Appendage (LAA) leading to thrombus formation and cerebral embolization. +-----------------------------------------------------------------------------+

  • | CHA2DS2-VASc STROKE RISK SCORING SYSTEM |
  • | |
  • | RISK FACTOR POINTS ASSIGNED|
  • | ----------------------------------------------------------------------- |
  • | C - Congestive Heart Failure (or LVEF <= 40%) 1 |
  • | H - Hypertension (or on antihypertensive therapy) 1 |
  • | A2- Age >= 75 years 2 |
  • | D - Diabetes Mellitus 1 |
  • | S2- Prior Stroke, TIA, or Thromboembolism 2 |
  • | V - Vascular Disease (Prior MI, PAD, or Aortic Plaque) 1 |
  • | A - Age 65 to 74 years 1 |
  • | Sc- Sex Category: Female 1 |
  • | ----------------------------------------------------------------------- |
  • | MAXIMUM POSSIBLE SCORE: 9 |
  • +-----------------------------------------------------------------------------+

Anticoagulation Decision Matrix & DOAC Dosing: +-----------------------------------------------------------------------------+

  • | ANTICOAGULATION THRESHOLDS IN NON-VALVULAR AFIB |
  • | |
  • | MEN: SCORE >= 2 | WOMEN: SCORE >= 3 ---> ORAL ANTICOAGULATION (OAC) |
  • | STRONGLY RECOMMENDED (CLASS 1)|
  • | |
  • | MEN: SCORE = 1 | WOMEN: SCORE = 2 ---> OAC MAY BE CONSIDERED |
  • | (CLASS 2b) |
  • | |
  • | MEN: SCORE = 0 | WOMEN: SCORE = 1 ---> NO ANTITHROMBOTIC THERAPY |
  • | (Omit Aspirin and OAC) |
  • +-----------------------------------------------------------------------------+
  • DOACs vs. Warfarin Comparison Table

Anticoagulant Agent Dosing & Regimens Mechanism Clinical Pearls & Renal Thresholds

Apixaban (Eliquis) Standard: 5 mg BID ; Reduced: 2.5 mg BID if ≥ 2 \ge 2 ≥ 2 of: Age ≥ 80 \ge 80 ≥ 80 , Weight ≤ 60 kg \le 60\text{ kg} ≤ 60 kg , SCr ≥ 1.5 mg/dL \text{SCr} \ge 1.5\text{ mg/dL} SCr ≥ 1.5 mg/dL Direct Factor Xa Inhibitor Preferred DOAC (ARISTOPHANES / ARISTOTLE trials: lowest bleeding, superior stroke reduction). Safe in mild-to-moderate CKD; reversal agent: Andexanet alfa.

Rivaroxaban (Xarelto) Standard: 20 mg daily with evening meal ; Reduced: 15 mg daily if CrCl 15 – 50 mL/min \text{CrCl } 15–50\text{ mL/min} CrCl 15–50 mL/min Direct Factor Xa Inhibitor Once-daily dosing; must be taken with food to ensure absorption. Reversal agent: Andexanet alfa.

Dabigatran (Pradaxa) Standard: 150 mg BID ; Reduced: 75 mg BID if CrCl 15 – 30 mL/min \text{CrCl } 15–30\text{ mL/min} CrCl 15–30 mL/min Direct Thrombin (IIa) Inhibitor Keep in original bottle (moisture sensitive). Higher dyspepsia rate (10%). Reversal agent: Idarucizumab (Praxbind).

Warfarin (Coumadin) Dose adjusted to Target INR 2.0–3.0 Vitamin K Epoxide Reductase Inhibitor (Factors II, VII, IX, X, Protein C/S) MANDATORY over DOACs in Valvular AFib (defined as moderate-to-severe mitral stenosis or mechanical prosthetic heart valves ). Monitored via PT/INR. Reversal: Vitamin K, 4-Factor PCC.

Note

Aspirin Obsolete for AFib Stroke Prevention: Antiplatelet monotherapy (Aspirin) or dual antiplatelet therapy (Aspirin + Clopidogrel) is no longer recommended for stroke prevention in atrial fibrillation. Clinical trials have demonstrated that aspirin provides negligible stroke protection in AFib while incurring major bleeding rates comparable to oral anticoagulants.

7. Peripheral Artery Disease (PAD): ABI & Claudication Management

Lower extremity Peripheral Artery Disease (PAD) is an atherosclerotic disorder causing arterial luminal stenosis, impairing distal skeletal muscle perfusion during ambulation. +-----------------------------------------------------------------------------+

  • | ANKLE-BRACHIAL INDEX (ABI) FORMULA |
  • | |

| \text{ABI} = \frac{\text{Highest Systolic Pressure in Ankle}}{\text{Highest Systolic Pressure in Both Arms}}|

  • | |
  • | - Measure with handheld continuous-wave Doppler and blood pressure cuff |
  • | - Ankle pressure: take higher of Posterior Tibial (PT) or Dorsalis Pedis |

+-----------------------------------------------------------------------------+ +-----------------------------------------------------------------------------+

  • | ABI CLINICAL INTERPRETATION |
  • | |
  • | ABI VALUE CLINICAL DIAGNOSIS & STAGING |
  • | ----------------------------------------------------------------------- |
  • | 1.00 - 1.40 NORMAL ARTERIAL PERFUSION |
  • | 0.91 - 0.99 BORDERLINE PERFUSION (Consider post-exercise ABI) |
  • | <= 0.90 DIAGNOSTIC OF PERIPHERAL ARTERY DISEASE (PAD) |
  • | 0.71 - 0.90 - Mild Arterial Obstruction (Claudication) |
  • | 0.41 - 0.70 - Moderate Obstruction (Severe Claudication) |
  • | <= 0.40 - Severe Obstruction / Critical Limb Ischemia |
  • | > 1.40 NON-COMPRESSIBLE / CALCIFIED ARTERIES |
  • | (Medial sclerosis in DM/ESRD; order TOE-BRACHIAL |
  • | INDEX [TBI]; abnormal if TBI <= 0.70) |
  • +-----------------------------------------------------------------------------+

Comprehensive Management of PAD:

Systemic ASCVD Risk Modification (Mandatory):

High-Intensity Statin: Atorvastatin 80 mg or Rosuvastatin 40 mg daily.

Antiplatelet Monotherapy: Aspirin 81 mg daily OR Clopidogrel 75 mg daily (CAPRIE trial demonstrated slight superiority of clopidogrel in PAD).

Dual Pathway Inhibition (COMPASS Protocol): Low-dose Rivaroxaban 2.5 mg BID plus Aspirin 81 mg daily reduces major adverse limb events (amputation) and MACE in high-risk PAD.

Smoking Cessation: The single most critical modifiable factor to halt disease progression.

Symptomatic Claudication Interventions:

Supervised Exercise Therapy (SET): First-line therapy (Class 1) . 30–45 minutes of treadmill walking 3–5 times per week for at least 12 weeks. Patient walks to moderate-to-severe claudication pain, rests until pain resolves, then resumes walking. Increases pain-free walking distance by 150–200%.

Cilostazol (100 mg orally BID): Phosphodiesterase-3 (PDE-3) inhibitor; promotes arterial vasodilation and inhibits platelet aggregation. Increases maximum walking distance.

Warning

Black Box Warning for Cilostazol: Cilostazol is strictly contraindicated in patients with heart failure of any severity (NYHA Class I–IV or reduced LVEF) . PDE-3 inhibitors possess inotropic properties that increase ventricular arrhythmias and mortality in heart failure patients.

8. Chronic Venous Insufficiency (CVI) & Vascular Ulcer Differential

Chronic Venous Insufficiency (CVI) results from incompetent venous valves and venous hypertension, leading to lower extremity venous pooling, capillary leak, and skin breakdown. +-----------------------------------------------------------------------------+

  • | ARTERIAL VS. VENOUS LOWER EXTREMITY ULCERS |
  • | |
  • | FEATURE ARTERIAL INSUFFICIENCY VENOUS INSUFFICIENCY |
  • | ----------------------------------------------------------------------- |
  • | LOCATION Distal tips of toes, heels, Medial malleolus, gaiter|
  • | lateral malleolus, metatarsal area (lower medial leg)|
  • | APPEARANCE "Punched out", round, smooth Shallow, irregular |
  • | edges, pale/necrotic base margins, ruddy red base|
  • | EXUDATE Minimal to dry Copious, heavy exudate |
  • | PAIN Severe; worsened by leg Dull ache / heaviness; |
  • | elevation; relieved by improved by elevation |
  • | dependent dangling and compression |
  • | PULSES Diminished or ABSENT NORMAL (may be hidden |
  • | by edema) |
  • | SKIN FINDINGS Pale on elevation, dependent Hyperpigmentation |
  • | rubor; cool, shiny, hairless (hemosiderin), stasis |
  • | skin, thickened nails dermatitis, lipodermato-|
  • | sclerosis, warm skin |
  • | TREATMENT FOCUS Revascularization; NO GRADUATED COMPRESSION |
  • | compression! (20-30 mmHg); Elevation|
  • +-----------------------------------------------------------------------------+

Caution

Compression Contraindication in Combined Disease: Never apply high-grade graduated compression stockings (30–40 mmHg) or Unna boots to a patient with chronic venous stasis ulcers without first verifying arterial competence via Ankle-Brachial Index (ABI) . Applying compression therapy when underlying arterial disease is present ( ABI < 0.60 – 0.70 \text{ABI} < 0.60–0.70 ABI < 0.60–0.70 ) occludes residual arterial inflow and precipitates acute ischemic limb gangrene.